<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923335</url>
  </required_header>
  <id_info>
    <org_study_id>Luo-20190326</org_study_id>
    <nct_id>NCT03923335</nct_id>
  </id_info>
  <brief_title>The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer</brief_title>
  <official_title>The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the predictive value of a four-gene methylation assay called
      Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups:
      high risk group and low risk group. The primary endpoint is 5 year disease free survival
      (DFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current risk stratification system defined by clinicopathological features does not
      identify the risk of disease recurrence in patients with early-stage colorectal cancer (CRC)
      with optimal accuracy. The investigators aimed to investigate whether the epigenetic
      alterations could serve as novel prognostic biomarkers that would improve the accuracy of the
      current primary tumor, regional nodes, metastasis (TNM) staging system.

      In the current study, the Investigators have analyzed the genome-wide methylation status of
      cytosine-phosphate-guanosine (CpG) sites using Infinium MethylationEPIC array in primary
      tumor and adjacent normal samples from 23 recurrent and 22 recurrence-free stage I and II CRC
      patients to identify potential methylation markers for disease-free survival (DFS). The
      prognostic value of the candidate biomarkers has been evaluated in a training cohort (n=174)
      and an independent validation cohort (n=267), and is to be validated in a prospective cohort
      (estimated n=287).

      Comprehensive data analysis identified a subset of methylated CpG loci that associated with a
      high risk of recurrence. Methylated CpGs in four genes were significantly associated with DFS
      in multivariate analysis in both training and validation cohort. Moreover, Hypermethylated
      Genes Counts panel using these four markers showed a higher prognostic value than any
      clinicopathological factor, current molecular biomarkers or single methylated CpG marker
      alone in the training and validation cohorts. This four-gene methylation assay is defined as
      Guangzhou Panel.

      The investigators aim to conduct a prospective observational study to evaluate the predictive
      value of Guangzhou Panel in early-stage colorectal cancer. A total of 287 patients with
      pathologically verified stage I-II CRC and underwent surgical resection are expected to be
      recruited in our study. These patients will be divided into high-risk group and low-risk
      group and will be followed up at least 5 years. The primary endpoint is 5-year disease free
      survival (DFS). The prognostic strength of candidate biomarkers was adjusted in multivariate
      Cox regression models including multiple biomarkers and clinicopathologic variables.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>From date of operation until the date of first recurrence or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
    <description>the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">287</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>high-risk group</arm_group_label>
    <description>patients with any of the four genes hypermethylated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low-risk group</arm_group_label>
    <description>patients with none of the four genes hypermethylated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DNA methylation detection</intervention_name>
    <description>detecting the methylation status of colorectal cancer specimen</description>
    <arm_group_label>high-risk group</arm_group_label>
    <arm_group_label>low-risk group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue specimen from colorectal cancer patients who underwent radical resection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients that had pathologically verified stage I-II CRC and underwent surgical resection
        in Sixth Affiliate Hospital of Sun Yat-sen University
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. TNM stage I-II (T1-4N0M0) colorectal cancer cases

          2. receive radical surgical resection

          3. have completed data of tumor location, histological type, behavioral characteristics
             or TNM staging

          4. have tumor specimens and either a valid microsatellite instability (MSI) or
             immuno-histochemistry (IHC) data

          5. have valid V-raf murine sarcoma viral oncogene homolog B1 (BRAF), kirsten rat sarcoma
             viral oncogene (KRAS), CpG island methylator phenotype (CIMP) results

          6. have at least 4 years of follow-up

          7. have valid time to local recurrence/metastasis in follow-up

          8. have clinical/treatment record data and valid preoperative status of intestinal
             obstruction or perforation (IOP), counts of lymph node removed in surgical resection.

        Exclusion Criteria:

          1. have had a previous diagnosis of any cancer or presence of any tumor other than the
             CRC

          2. have had inflammatory bowel disease

          3. have had hereditary colorectal cancer syndromes, including Familial adenomatous
             polyposis, mutyh (MYH)-associated polyposis, Peutz-Jeghers syndrome, Juvenile
             polyposis coli, phosphate and tension homology deleted on chromosome ten (PTEN)
             tumor-hamartoma syndromes, Lynch Syndrome, and Familial Colorectal Cancer Type X.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanxin Luo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanxin Luo, MD,PhD</last_name>
    <phone>+86-13826190263</phone>
    <email>luoyx25@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Du Cai, MD</last_name>
    <phone>+86-18819481550</phone>
    <email>caid6@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliate Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanxin Luo, PhD,MD</last_name>
      <phone>+86-13826190263</phone>
      <email>luoyx25@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Du Cai, MD</last_name>
      <phone>+86-18819481550</phone>
      <email>caid6@mail2.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.</citation>
    <PMID>29313949</PMID>
  </reference>
  <reference>
    <citation>O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1;29(25):3381-8. doi: 10.1200/JCO.2010.34.3426. Epub 2011 Jul 25.</citation>
    <PMID>21788561</PMID>
  </reference>
  <reference>
    <citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490-1502. doi: 10.1016/S0140-6736(13)61649-9. Epub 2013 Nov 11. Review.</citation>
    <PMID>24225001</PMID>
  </reference>
  <reference>
    <citation>Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15;370(9604):2020-9.</citation>
    <PMID>18083404</PMID>
  </reference>
  <reference>
    <citation>Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut. 2007 Oct;56(10):1419-25. Epub 2007 May 9.</citation>
    <PMID>17494107</PMID>
  </reference>
  <reference>
    <citation>Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17;349(3):247-57.</citation>
    <PMID>12867608</PMID>
  </reference>
  <reference>
    <citation>Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Walker SM, Mulligan JM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe OF, Winqvist O, Manne U, Shanmugam C, Ramaswamy S, Leon EJ, Smith WI Jr, McDermott U, Wilson RH, Longley D, Marshall J, Cummins R, Sargent DJ, Johnston PG, Harkin DP. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011 Dec 10;29(35):4620-6. doi: 10.1200/JCO.2011.35.4498. Epub 2011 Nov 7.</citation>
    <PMID>22067406</PMID>
  </reference>
  <reference>
    <citation>Esteller M. Epigenetics in cancer. N Engl J Med. 2008 Mar 13;358(11):1148-59. doi: 10.1056/NEJMra072067. Review.</citation>
    <PMID>18337604</PMID>
  </reference>
  <reference>
    <citation>Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N Engl J Med. 2018 Apr 5;378(14):1323-1334. doi: 10.1056/NEJMra1402513. Review.</citation>
    <PMID>29617578</PMID>
  </reference>
  <reference>
    <citation>Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006 Jul;38(7):787-93. Epub 2006 Jun 25.</citation>
    <PMID>16804544</PMID>
  </reference>
  <reference>
    <citation>Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008 Mar 13;358(11):1118-28. doi: 10.1056/NEJMoa0706550.</citation>
    <PMID>18337602</PMID>
  </reference>
  <reference>
    <citation>Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012 Feb;22(2):271-82. doi: 10.1101/gr.117523.110. Epub 2011 Jun 9.</citation>
    <PMID>21659424</PMID>
  </reference>
  <reference>
    <citation>Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, Wang J, Willis JE, Makar KW, Ulrich CM, Lutterbaugh JD, Shrubsole MJ, Zheng W, Markowitz SD, Grady WM. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology. 2014 Aug;147(2):418-29.e8. doi: 10.1053/j.gastro.2014.04.039. Epub 2014 Apr 30.</citation>
    <PMID>24793120</PMID>
  </reference>
  <reference>
    <citation>Martínez-Cardús A, Moran S, Musulen E, Moutinho C, Manzano JL, Martinez-Balibrea E, Tierno M, Élez E, Landolfi S, Lorden P, Arribas C, Müller F, Bock C, Tabernero J, Esteller M. Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology. 2016 Nov;151(5):961-972. doi: 10.1053/j.gastro.2016.08.001. Epub 2016 Aug 10.</citation>
    <PMID>27521480</PMID>
  </reference>
  <reference>
    <citation>Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, Van Djik S, Muhlhausler B, Stirzaker C, Clark SJ. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016 Oct 7;17(1):208.</citation>
    <PMID>27717381</PMID>
  </reference>
  <reference>
    <citation>Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2016 Mar;8(3):389-99. doi: 10.2217/epi.15.114. Epub 2015 Dec 17.</citation>
    <PMID>26673039</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>prognostic biomarkers</keyword>
  <keyword>DNA Methylation</keyword>
  <keyword>gene panel</keyword>
  <keyword>recurrence</keyword>
  <keyword>disease free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Our DNA methylation panel is applying for patent protection, therefore we plan to keep the data private for the time being.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

